MedWatch

Ferring VP steps down as chair of API manufacturer

Shortly after Ferring subsidiary Syntese A/S brought in a new CEO from Novo Nordisk, the company bids farewell to its chair, Marienne Kock, senior vice president and general manager at Ferring Denmark. Syntese supplies firms worldwide with the active pharmaceutical ingredient (API), mesalazine.

Photo: Thomas Borberg

A Ferring Pharmaceuticals subsidiary, Syntese A/S, has in a brief period changed out both its CEO and chair of the board of directors, according to the Danish Central Business Register (CVR).

The company reports that Marianne Kock, who’s also the senior vice president and general manager at parent company Ferring in Denmark, has stepped down from her position as chair of the board of Syntese, which manufactures the active ingredient mesalazine used to treat inflammatory bowel diseases like ulcerative colitis and Crohn’s disease.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs